|Bid||0.00 x 2200|
|Ask||0.00 x 2900|
|Day's range||6.56 - 6.74|
|52-week range||3.71 - 18.98|
|Beta (5Y monthly)||3.24|
|PE ratio (TTM)||N/A|
|Earnings date||21 Sep 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
After the markets close Sept. 21, Aurora Cannabis (NASDAQ: ACB) will release results for its fiscal fourth quarter, which ended June 30. The troubled Canadian pot company's stock is already down by about 20% year to date -- a sharp contrast to the sector benchmark Horizons Marijuana Life Sciences ETF, which is up 5% -- and the upcoming report could be pivotal in determining whether the share price gets out of the red for 2021. Investors aren't expecting to see Aurora turn a profit in the final quarter of its fiscal year, but there are other ways that the company can show it is making progress.
Aurora Cannabis Inc. (ACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
When marijuana companies report their earnings, the focus for investors typically goes to how much their sales grew and how profitable the businesses are. What's arguably more important than revenue growth and profitability is cash flow from operations. The reason is that if a company is burning through cash from its day-to-day activities, it can be a sign that share issues and dilution are inevitable, which can offset any bullishness that sales and profit growth might generate.